Director of Odisha agency, two different workers arrested over spurious Covid-19 medication commerce
2 min read
By Express News Service
BHUBANESWAR: The Special Task Force (STF) of the Crime Branch on Wednesday arrested the director and two different workers of Cuttack-based Medilloyd Medicament Private Limited for his or her alleged involvement within the spurious Covid-19 medication commerce.
Crime Branch sources mentioned Medilloyd Medicament had procured Favimax-400 tablets from Max Relief Healthcare whose proprietor Sudeep Mukherjee was earlier arrested by the Mumbai police for allegedly manufacturing and supplying pretend Covid-19 medication to Maharashtra and different states.
“Multiple teams were formed and investigation into the matter was launched at various places. Currently, the probe is continuing in Odisha, West Bengal and Maharashtra,” Crime Branch ADG YK Jethwa advised the reporters.
Mukherjee’s doubtful firm Max Relief had manufactured Favimax tablets and was supplying them to numerous components of the nation. Apart from him, yet another individual was additionally nabbed by Mumbai Police in reference to the pretend Covid-19 medication commerce.
“Our team is in Mumbai to collect more evidence. Medilloyd Medicament had procured Favimax tablets from Max Relief at a very low cost and it had supplied to another trader in Gwalior. The STF has traced and frozen three bank accounts with deposited amount of over Rs 50 lakh of Medilloyd’s director and two other accused. Further probe is on,” mentioned Jethwa.
Medilloyd had reportedly procured one strip of Favimax-400 (10 tablets) for Rs 65 and had deliberate to sale it for Rs 1,290.
Chief Minister Naveen Patnaik had ordered a Crime Branch probe into the alleged spurious medication commerce on June 14 after pretend Favipiravir tablets have been seized from the wholesaler in Cuttack earlier within the month.
Based on the grievance filed by the Directorate of Drugs Control Administration, the STF had registered a case on this connection underneath Sections 275, 276, 420, 467, 468, 471 and 120B of IPC and Section 27(c) of Drugs and Cosmetics Act.
